CollaGenex Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration has approved two phase 3 clinical trials of Col-101, a once-daily, modified-released formulation of doxycycline, 40 mg, for treatment of rosacea.
Brittany Scurto, PA-C: How to Discuss an Integrative Medicine Approach With Patients
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Atopic Dermatitis Identified as Possible Risk Factor for Headache Disorders, Migraine
ReV Up Your Vitiligo Treatment Strategies
Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment and Stigmatization
Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma